To the Editor: In their study of the Age-Related Eye Disease Study (AREDS) participants,1 Dr Seddon and colleagues investigated whether genetic variants were associated with progression of age-related macular degeneration. In the article, they did not present the main results stratified by treatment assignment. Results for the antioxidants-plus-zinc group and the placebo group would have been a useful addition to Table 6 in the article. The authors did note that genotype and treatment had no significant interaction, but interaction tests may have very low statistical power.
Providing these specific results would also help interpret the corrected abstract conclusion: “Presence of these polymorphisms plus smoking and body mass index of 25 or higher, controlling for AREDS vitamin-mineral treatment, identifies patients who are highly susceptible to developing advanced stages of this visually disabling disease.”1 The treatment used in AREDS appears to be one of the few options to help manage this public health problem,2 but high doses of vitamin E (an essential component of AREDS treatment) can be harmful,3 making this additional information important.
Financial Disclosures: Dr Damián reports having received research support from Pfizer.
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Comments are moderated and will appear on the site at the discretion of the Journal of American Medical Association editors. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Customize your page view by dragging & repositioning the boxes below.
and access these and other features:
Register Now
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.